sulforaphane and Disease Models, Animal studies

sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

Excerpt	Relevance	Reference
"The efficacy of the sulforaphane derivative JY4 was evaluated in acute and chronic mouse models of ulcerative colitis induced by dextran sodium sulfate."	8.12	Therapeutic effect of the sulforaphane derivative JY4 on ulcerative colitis through the NF-κB-p65 pathway. ( Bai, CG; Bai, WF; Sun, TY; Wang, TX; Yang, YF; Zhang, YR; Zhao, XJ, 2022)
"The aetiology of gout is closely linked to the deposition of monosodium uric acid (MSU) crystals and the consequent activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome."	7.88	Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Yang, G; Yeon, SH, 2018)
" We sought to investigate potential combinatorial effects of epigenetic bioactive botanicals including epigallocatechin-3-gallate (EGCG) in green tea polyphenols (GTPs) and sulforaphane (SFN) in broccoli sprouts (BSp) on neutralizing epigenetic aberrations in estrogen receptor-α (ERα) leading to enhanced anti-hormone therapeutic efficacy in ERα-negative breast cancer."	7.85	Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression. ( Li, Y; Meeran, SM; Tollefsbol, TO, 2017)
" Sulforaphane could be a new therapeutic approach to improve cognitive and motor function in hyperammonemia, hepatic encephalopathy, and other pathologies associated with neuroinflammation by promoting microglia differentiation from M1 to M2."	7.83	Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. ( Agusti, A; Balzano, T; Cabrera-Pastor, A; Felipo, V; Gonzalez-Usano, A; Hernandez-Rabaza, V; Llansola, M; Taoro-Gonzalez, L, 2016)
"The purpose of this study was to investigate the effect of Sulforaphane on ischemia/ reperfusion (IR) injury of the liver and distant organs resulting from liver blood flow arrest."	7.81	The effects of sulforaphane on the liver and remote organ damage in hepatic ischemia-reperfusion model formed with pringle maneuver in rats. ( Alabalik, U; Kapan, M; Kaplan, I; Oguz, A; Polat, Y; Turkoglu, A; Ulger, BV; Uslukaya, O, 2015)
"Intraperitoneal injection of the phytochemicals EGCG, SFN, resveratrol, and allicin have suppressive effects on the development of intimal hyperplasia in the carotid artery injury model, with maximal effect due to EGCG."	7.79	Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery. ( Czernizer, E; Dardik, A; Dardik, H; Hoffmann, T; London, D; Naftalovich, R; Orozco-Sevilla, V; Yang, C, 2013)
" In this study, we attempt to determine whether sulforaphane regulates the inflammatory response in an ovalbumin (OVA)-induced murine asthma model."	7.78	Sulforaphane inhibits the Th2 immune response in ovalbumin-induced asthma. ( Chung, SW; Heo, DR; Jung, ID; Kim, JW; Kim, YD; Lee, CM; Noh, KT; Park, JH; Park, JW; Park, YM; Seo, JK; Shin, YK, 2012)
"Sulforaphane (SFN) has a strong anti-inflammatory ability and a certain protective effect on intestinal diseases."	5.91	The Protective Effect of Sulforaphane on ER-induced Apoptosis and Inflammation in Necrotizing Enterocolitis Mice. ( Bao, Z; Mi, Y; Wang, X; Xiong, X, 2023)
"Psoriasis is a chronic inflammatory skin disease that affects millions of people worldwide."	5.91	Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling. ( Gu, C; Huang, Z; Li, L; Lian, P; Lu, R; Lu, Y; Ma, C; Peng, Z; Pu, W; Ruan, B; Su, Z; Wang, H; Wang, W; Wazir, J; Wei, L; Zong, Y, 2023)
"Sulforaphane was reported to ameliorate inflammatory responses."	5.72	Attenuation of experimentally induced atopic dermatitis in mice by sulforaphane: effect on inflammation and apoptosis. ( Alyoussef, A, 2022)
"Hypospadias is a common malformation of the penis."	5.72	An experimental evaluation of the efficacy of perinatal sulforaphane supplementation to decrease the incidence and severity of vinclozolin-induced hypospadias in the mouse model. ( Amato, CM; Bereman, M; Fricke, A; Marella, S; McCoy, KA; Mogus, JP, 2022)
"Treatment with sulforaphane or albumin resulted in the preservation of goblet cells (P < 0."	5.62	Sulforaphane and Albumin Attenuate Experimental Intestinal Ischemia-Reperfusion Injury. ( Bittencourt Rosas, SL; Dos Santos Valença, S; Franco, OB; Lima Castelo-Branco, MT; Lopes Lichtenberger, RC; Maran Carra, A; Pereira de Souza, HS; Ribeiro, BE; Sampaio de Holanda, G; Santana, PT; Schanaider, A, 2021)
"Sulforaphane was administered intraperitoneally at the dose of 5, 15, 30 and 60 mg/kg/day for 28 days."	5.56	Anti-nociceptive and anti-inflammatory effects of sulforaphane on sciatic endometriosis in a rat model. ( Jiang, J; Liu, Y; Lu, X; Meng, J; Qin, X; Zhang, Z, 2020)
"Intestinal ischemia reperfusion injury (IRI) is an inherent, unavoidable event of intestinal transplantation, contributing to allograft failure and rejection."	5.56	Sulforaphane Elicits Protective Effects in Intestinal Ischemia Reperfusion Injury. ( Becker, F; Brockmann, JG; Chen, Z; Hansen, U; Heitplatz, B; Mohr, A; Pascher, A, 2020)
"Sulforaphane treatment led to induction of antioxidant enzymes (SOD, GPx) in AECs and pulmonary non-enzymatic antioxidants."	5.51	Sulforaphane treatment reverses corticosteroid resistance in a mixed granulocytic mouse model of asthma by upregulation of antioxidants and attenuation of Th17 immune responses in the airways. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alqahtani, F; Alqinyah, M; AlThagfan, SS; Ibrahim, KE; Nadeem, A, 2019)
"Autism is a neurodevelopmental disease which is characterized by its core behavioral symptoms such as impairment in social interaction and stereotyped repetitive behavior."	5.51	Nrf2 activator, sulforaphane ameliorates autism-like symptoms through suppression of Th17 related signaling and rectification of oxidant-antioxidant imbalance in periphery and brain of BTBR T+tf/J mice. ( Ahmad, SF; Al-Harbi, NO; Alqahtani, F; Alqinyah, M; Attia, SM; Bakheet, SA; Ibrahim, KE; Nadeem, A, 2019)
"Sulforaphane (SFN) is a natural compound that has been suggested as an antioxidant."	5.48	Sulforaphane Modulates Joint Inflammation in a Murine Model of Complete Freund's Adjuvant-Induced Mono-Arthritis. ( Abreu-Silva, AL; da Penha, TA; de Aquino, AF; de Sá, JC; de Souza, BGGF; Fialho Sousa, NC; França Muniz, T; Grisotto, MAG; Nascimento da Silva, LC; Neuza da Silva Nina, L; Silva E Silva, C; Silva Rodrigues, JF; Soares Fernandes, E, 2018)
"Sulforaphane (SFN) has been confirmed to be an effective antioxidant in the treatment of many diseases."	5.46	Protective effect of sulforaphane against retinal degeneration in the Pde6 ( Kang, K; Yu, M, 2017)
"Pulmonary fibrosis was induced in C57/BL6 mice by intratracheal instillation of BLM."	5.46	Sulforaphane prevents bleomycin‑induced pulmonary fibrosis in mice by inhibiting oxidative stress via nuclear factor erythroid 2‑related factor‑2 activation. ( Hu, Y; Ma, T; Ma, Z; Rong, G; Shi, S; Yan, B; Yang, J, 2017)
"Treatment with sulforaphane could be useful to improve cognitive function in cirrhotic patients with minimal or clinical hepatic encephalopathy."	5.43	Hyperammonemia induces glial activation, neuroinflammation and alters neurotransmitter receptors in hippocampus, impairing spatial learning: reversal by sulforaphane. ( Agustí, A; Cabrera-Pastor, A; Felipo, V; Hernández-Rabaza, V; Llansola, M; Malaguarnera, M; Taoro-González, L, 2016)
"Multiple myeloma is a fatal disease characterized by clonal proliferation of plasma cells in the bone marrow."	5.37	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. ( Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Hideshima, T; Jakubikova, J; Kim, K; Klippel, S; Leiba, M; McMillin, DW; Mitsiades, CS; Nahar, S; Negri, J; Ooi, M; Richardson, PG; Sedlak, J, 2011)
"The efficacy of the sulforaphane derivative JY4 was evaluated in acute and chronic mouse models of ulcerative colitis induced by dextran sodium sulfate."	4.12	Therapeutic effect of the sulforaphane derivative JY4 on ulcerative colitis through the NF-κB-p65 pathway. ( Bai, CG; Bai, WF; Sun, TY; Wang, TX; Yang, YF; Zhang, YR; Zhao, XJ, 2022)
"The ovalbumin-induced (OVA) chronic allergic airways murine model is a well-established model for investigating pre-clinical therapies for chronic allergic airways diseases, such as asthma."	3.96	Investigation of molecular mechanisms of experimental compounds in murine models of chronic allergic airways disease using synchrotron Fourier-transform infrared microspectroscopy. ( Bambery, KR; Karagiannis, TC; Licciardi, PV; Mazarakis, N; Royce, SG; Samuel, CS; Snibson, KJ; Tobin, MJ; Ververis, K; Vongsvivut, J, 2020)
"The aetiology of gout is closely linked to the deposition of monosodium uric acid (MSU) crystals and the consequent activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome."	3.88	Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. ( Cho, YY; Kang, HC; Lee, HE; Lee, HS; Lee, JY; Yang, G; Yeon, SH, 2018)
" We sought to investigate potential combinatorial effects of epigenetic bioactive botanicals including epigallocatechin-3-gallate (EGCG) in green tea polyphenols (GTPs) and sulforaphane (SFN) in broccoli sprouts (BSp) on neutralizing epigenetic aberrations in estrogen receptor-α (ERα) leading to enhanced anti-hormone therapeutic efficacy in ERα-negative breast cancer."	3.85	Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression. ( Li, Y; Meeran, SM; Tollefsbol, TO, 2017)
" Sulforaphane could be a new therapeutic approach to improve cognitive and motor function in hyperammonemia, hepatic encephalopathy, and other pathologies associated with neuroinflammation by promoting microglia differentiation from M1 to M2."	3.83	Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. ( Agusti, A; Balzano, T; Cabrera-Pastor, A; Felipo, V; Gonzalez-Usano, A; Hernandez-Rabaza, V; Llansola, M; Taoro-Gonzalez, L, 2016)
"Biliatresone is an electrophilic isoflavone isolated from Dysphania species plants that has been causatively linked to naturally occurring outbreaks of a biliary atresia (BA)-like disease in livestock."	3.83	Glutathione antioxidant pathway activity and reserve determine toxicity and specificity of the biliary toxin biliatresone in zebrafish. ( Blair, I; Gillespie, K; Koo, KA; Lorent, K; Marchione, DM; Pack, M; Porter, JR; Shin, D; So, J; Waisbourd-Zinman, O; Wells, RG; Wilkins, BJ; Zhao, X, 2016)
"Dihydrotestosterone (DHT) causes the regression of human hair follicles in the parietal scalp, leading to androgenic alopecia (AGA)."	3.83	Sulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone. ( Sasaki, M; Shimokado, K; Shinozaki, S, 2016)
"The purpose of this study was to determine the effect of sulforaphane (SFN) on hepatic ischemia reperfusion injury (HIRI) and to explore the underlying mechanisms."	3.81	Sulforaphane reduces apoptosis and oncosis along with protecting liver injury-induced ischemic reperfusion by activating the Nrf2/ARE pathway. ( Alina, A; Chi, X; Jin, Y; Lin, S; Shen, N; Yang, S; Zhang, R, 2015)
"The purpose of this study was to investigate the effect of Sulforaphane on ischemia/ reperfusion (IR) injury of the liver and distant organs resulting from liver blood flow arrest."	3.81	The effects of sulforaphane on the liver and remote organ damage in hepatic ischemia-reperfusion model formed with pringle maneuver in rats. ( Alabalik, U; Kapan, M; Kaplan, I; Oguz, A; Polat, Y; Turkoglu, A; Ulger, BV; Uslukaya, O, 2015)
"Intraperitoneal injection of the phytochemicals EGCG, SFN, resveratrol, and allicin have suppressive effects on the development of intimal hyperplasia in the carotid artery injury model, with maximal effect due to EGCG."	3.79	Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery. ( Czernizer, E; Dardik, A; Dardik, H; Hoffmann, T; London, D; Naftalovich, R; Orozco-Sevilla, V; Yang, C, 2013)
" In this study, we attempt to determine whether sulforaphane regulates the inflammatory response in an ovalbumin (OVA)-induced murine asthma model."	3.78	Sulforaphane inhibits the Th2 immune response in ovalbumin-induced asthma. ( Chung, SW; Heo, DR; Jung, ID; Kim, JW; Kim, YD; Lee, CM; Noh, KT; Park, JH; Park, JW; Park, YM; Seo, JK; Shin, YK, 2012)
" By virtue of its lipophilic nature and low molecular weight, sulforaphane displays significantly higher bioavailability than the polyphenol-based dietary supplements that also activate Nrf2."	2.53	Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician's Expectation Be Matched by the Reality? ( Coombes, JS; Fassett, RG; Houghton, CA, 2016)
"This population is associated with cancer recurrence and is therefore clinically significant."	2.53	Targeting cancer stem-like cells using dietary-derived agents - Where are we now? ( Bayliss, R; Brown, K; Gescher, A; Howells, L; Karmokar, A; Khan, S; Thomas, AL, 2016)
" Based on these promising preliminary results, additional mechanistic studies are underway, as well as full-term carcinogenesis studies with chronic administration schedules."	2.43	Quinone reductase induction as a biomarker for cancer chemoprevention. ( Cuendet, M; Moon, RC; Oteham, CP; Pezzuto, JM, 2006)
"Sulforaphane (SFN) has a strong anti-inflammatory ability and a certain protective effect on intestinal diseases."	1.91	The Protective Effect of Sulforaphane on ER-induced Apoptosis and Inflammation in Necrotizing Enterocolitis Mice. ( Bao, Z; Mi, Y; Wang, X; Xiong, X, 2023)
"Psoriasis is a chronic inflammatory skin disease that affects millions of people worldwide."	1.91	Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling. ( Gu, C; Huang, Z; Li, L; Lian, P; Lu, R; Lu, Y; Ma, C; Peng, Z; Pu, W; Ruan, B; Su, Z; Wang, H; Wang, W; Wazir, J; Wei, L; Zong, Y, 2023)
"Sulforaphane was reported to ameliorate inflammatory responses."	1.72	Attenuation of experimentally induced atopic dermatitis in mice by sulforaphane: effect on inflammation and apoptosis. ( Alyoussef, A, 2022)
"Sulforaphane (SFN) is a kind of isothiocyanate from cruciferous vegetables with extensive anti-tumor activity."	1.72	mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma. ( Hou, G; Li, Y; Lu, Z; Wang, P; Wei, H; Xu, Y; Zhang, Y; Zhao, W, 2022)
"Hypospadias is a common malformation of the penis."	1.72	An experimental evaluation of the efficacy of perinatal sulforaphane supplementation to decrease the incidence and severity of vinclozolin-induced hypospadias in the mouse model. ( Amato, CM; Bereman, M; Fricke, A; Marella, S; McCoy, KA; Mogus, JP, 2022)
"Treatment with sulforaphane or albumin resulted in the preservation of goblet cells (P < 0."	1.62	Sulforaphane and Albumin Attenuate Experimental Intestinal Ischemia-Reperfusion Injury. ( Bittencourt Rosas, SL; Dos Santos Valença, S; Franco, OB; Lima Castelo-Branco, MT; Lopes Lichtenberger, RC; Maran Carra, A; Pereira de Souza, HS; Ribeiro, BE; Sampaio de Holanda, G; Santana, PT; Schanaider, A, 2021)
"Acrylamide is a well characterized neurotoxicant known to cause neuropathy and encephalopathy in humans and experimental animals."	1.62	Nrf2 Activation Attenuates Acrylamide-Induced Neuropathy in Mice. ( Davuljigari, CB; Ekuban, FA; Fergany, AAM; Ichihara, G; Morikawa, K; Zong, C, 2021)
"Sulforaphane was administered intraperitoneally at the dose of 5, 15, 30 and 60 mg/kg/day for 28 days."	1.56	Anti-nociceptive and anti-inflammatory effects of sulforaphane on sciatic endometriosis in a rat model. ( Jiang, J; Liu, Y; Lu, X; Meng, J; Qin, X; Zhang, Z, 2020)
"Intestinal ischemia reperfusion injury (IRI) is an inherent, unavoidable event of intestinal transplantation, contributing to allograft failure and rejection."	1.56	Sulforaphane Elicits Protective Effects in Intestinal Ischemia Reperfusion Injury. ( Becker, F; Brockmann, JG; Chen, Z; Hansen, U; Heitplatz, B; Mohr, A; Pascher, A, 2020)
"Depression is one of the most common behavioral and psychological symptoms in people with Alzheimer's disease (AD)."	1.56	Sulforaphane Reverses the Amyloid-β Oligomers Induced Depressive-Like Behavior. ( Jia, J; Li, T; Quan, M; Wang, W; Wei, C, 2020)
"Sulforaphane is an isothiocyanate, which is found in cruciferous vegetables."	1.51	Antitumor activity of sulforaphane in mice model of skin cancer via blocking sulfatase-2. ( Alyoussef, A; Taha, M, 2019)
"Sulforaphane is a Nrf2 activator but is unstable at ambient temperature."	1.51	SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis. ( Copple, IM; Franklin, S; Galea, I; Howat, DW, 2019)
"Sulforaphane treatment led to induction of antioxidant enzymes (SOD, GPx) in AECs and pulmonary non-enzymatic antioxidants."	1.51	Sulforaphane treatment reverses corticosteroid resistance in a mixed granulocytic mouse model of asthma by upregulation of antioxidants and attenuation of Th17 immune responses in the airways. ( Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alqahtani, F; Alqinyah, M; AlThagfan, SS; Ibrahim, KE; Nadeem, A, 2019)
"Autism is a neurodevelopmental disease which is characterized by its core behavioral symptoms such as impairment in social interaction and stereotyped repetitive behavior."	1.51	Nrf2 activator, sulforaphane ameliorates autism-like symptoms through suppression of Th17 related signaling and rectification of oxidant-antioxidant imbalance in periphery and brain of BTBR T+tf/J mice. ( Ahmad, SF; Al-Harbi, NO; Alqahtani, F; Alqinyah, M; Attia, SM; Bakheet, SA; Ibrahim, KE; Nadeem, A, 2019)
"Sulforaphane (SFN) is a phytochemical antioxidant known to affect multiple cellular targets including Nrf2-ARE pathway in chemoprevention."	1.51	Sulforaphane enriched transcriptome of lung mitochondrial energy metabolism and provided pulmonary injury protection via Nrf2 in mice. ( Bell, DA; Blankenship-Paris, T; Cho, HY; Deterding, L; Kleeberger, SR; Lih, F; Miller-DeGraff, L; Morgan, DL; Panduri, V; Reddy, AJ; Talalay, P; Wang, X; Yamamoto, M, 2019)
"Pachyonychia congenita is caused by mutations in keratin genes and typified by dystrophic lesions affecting nails, glands, oral mucosa, and palmar-plantar epidermis."	1.48	Sexual Dimorphism in Response to an NRF2 Inducer in a Model for Pachyonychia Congenita. ( Coulombe, PA; Hakim, JMC; Kerns, ML; Lu, RG; Zieman, A, 2018)
"Sulforaphane (SFN) is a natural compound that has been suggested as an antioxidant."	1.48	Sulforaphane Modulates Joint Inflammation in a Murine Model of Complete Freund's Adjuvant-Induced Mono-Arthritis. ( Abreu-Silva, AL; da Penha, TA; de Aquino, AF; de Sá, JC; de Souza, BGGF; Fialho Sousa, NC; França Muniz, T; Grisotto, MAG; Nascimento da Silva, LC; Neuza da Silva Nina, L; Silva E Silva, C; Silva Rodrigues, JF; Soares Fernandes, E, 2018)
"Sulforaphane is an herbal isothiocyanate enriched in cruciferous vegetables."	1.48	Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-β and Tau in a Mouse Model of Alzheimer's Disease. ( Choi, BR; Han, JS; Kim, J; LaFerla, FM; Lee, KW; Lee, S; Park, JHY, 2018)
" Metabolic profile, NO bioavailability and vascular oxidative stress, AGE and Nrf2 levels were also assessed."	1.46	The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes. ( Crisóstomo, J; Fernandes, R; Pereira, A; Seiça, RM; Sena, CM, 2017)
"Chemoresistant A549 lung cancer cells that display constitutive dominant hyperactivation of Nrf2 signaling are particularly vulnerable to VSVΔ51 oncolysis."	1.46	Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity. ( Beljanski, V; Chiang, C; Dinkova-Kostova, AT; Ferrari, M; Goulet, ML; Hadj, SB; Hiscott, J; Jiang, Y; Knatko, EV; Lababidi, RR; Lin, R; Liu, Y; Naidu, SD; Olagnier, D; Sze, A, 2017)
"Sulforaphane (SFN) is a thiol compound found in wide abundance in cruciferous plants that has numerous reported therapeutic efficacies."	1.46	Sulforaphane protects against sodium valproate-induced acute liver injury. ( Atef, H; El-Khouly, OA; Nazmy, EA; Said, E, 2017)
"Sulforaphane treatment resulted in a dose-dependent increase in the levels of tumor suppressive miR200c."	1.46	Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction. ( Liao, YW; Liu, CM; Lu, MY; Peng, CY; Tsai, ML; Yeh, JC; Yu, CC; Yu, CH, 2017)
"Pulmonary fibrosis was induced in C57/BL6 mice by intratracheal instillation of BLM."	1.46	Sulforaphane prevents bleomycin‑induced pulmonary fibrosis in mice by inhibiting oxidative stress via nuclear factor erythroid 2‑related factor‑2 activation. ( Hu, Y; Ma, T; Ma, Z; Rong, G; Shi, S; Yan, B; Yang, J, 2017)
"Sulforaphane (SFN) has been confirmed to be an effective antioxidant in the treatment of many diseases."	1.46	Protective effect of sulforaphane against retinal degeneration in the Pde6 ( Kang, K; Yu, M, 2017)
"Treatment with sulforaphane could be useful to improve cognitive function in cirrhotic patients with minimal or clinical hepatic encephalopathy."	1.43	Hyperammonemia induces glial activation, neuroinflammation and alters neurotransmitter receptors in hippocampus, impairing spatial learning: reversal by sulforaphane. ( Agustí, A; Cabrera-Pastor, A; Felipo, V; Hernández-Rabaza, V; Llansola, M; Malaguarnera, M; Taoro-González, L, 2016)
"Sulforaphane was also found to inhibit cell recruitment to the peritoneum and interleukin-1β secretion in an in vivo peritonitis model of acute gout and to reverse NLRP1-mediated murine resistance to Bacillus anthracis spore infection."	1.43	Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. ( Greaney, AJ; Leppla, SH; Maier, NK; Moayeri, M, 2016)
"Sulforaphane has been reported to protect against oxidative stress-mediated cell and tissue injury."	1.43	Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta. ( Matsui, T; Nakamura, N; Nishino, Y; Ojima, A; Yamagishi, SI, 2016)
"Sepsis is often characterized by an acute brain inflammation and dysfunction, which is associated with increased morbidity and mortality worldwide."	1.43	Sulforaphane induces neurovascular protection against a systemic inflammatory challenge via both Nrf2-dependent and independent pathways. ( Alexander, JS; Becker, F; Evans, PC; Gavins, FNE; Gillespie, S; Holloway, PM; Nguyen, V; Vital, SA, 2016)
"Sulforaphane appears to be a promising compound with neuroprotective properties that may play an important role in preventing PD."	1.43	Sulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways. ( Cai, X; Cao, P; Chen, B; Chen, J; Cheng, X; Hu, Z; Lu, W; Shen, J; Sun, X; Wang, X; Wu, L; Yan, H; Yang, J; Yang, Y; Ye, J; Zhou, Q, 2016)
"Sulforaphane (SFN) is a natural and highly effective antioxidant."	1.43	Sulforaphane Prevents Testicular Damage in Kunming Mice Exposed to Cadmium via Activation of Nrf2/ARE Signaling Pathways. ( Gao, F; Guo, Y; He, JB; Li, L; Li, P; Liu, MD; Long, M; Yang, SH; Yu, LH; Zhang, Y, 2016)
"Sulforaphane (SFN) is a natural compound with antioxidative, anti-inflammatory and neuroprotective activities."	1.43	Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice. ( Gao, Q; Gao, Y; Liang, Y; Ma, Y; Shi, H; Wang, X; Wu, S; Xi, Y; Zhao, P, 2016)
"Memory deficits were assessed using the object recognition task."	1.42	Sulforaphane rescues memory dysfunction and synaptic and mitochondrial alterations induced by brain iron accumulation. ( Aguzzoli, C; Bogo, MR; Dargél, VA; de Freitas, BS; de Lima, MN; Falavigna, L; Florian, PZ; Kist, LW; Köbe, LM; Lavich, IC; Piffero, B; Schröder, N, 2015)
"Following retinal ischemic reperfusion injury, vehicle (1% DMSO saline) or sulforaphane (25 mg/kg/day) was administered intraperitoneally daily for 5 days."	1.42	Protection of retinal function by sulforaphane following retinal ischemic injury. ( Ambrecht, LA; Bu, P; McDonnell, JF; Perlman, JI; Qiao, L; Zhai, Y, 2015)
"Sulforaphane was anticonvulsant in two acute mouse models of epilepsy and protected mice against pilocarpine-induced status epilepticus (SE)."	1.42	Sulforaphane is anticonvulsant and improves mitochondrial function. ( Borges, K; Carrasco-Pozo, C; Tan, KN, 2015)
"Although the etiology of Parkinson's disease (PD) remains elusive, recent studies suggest that oxidative stress contributes to the cascade leading to dopaminergic (DAergic) neurodegeneration."	1.40	Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy. ( Choi, JW; Han, SH; Hwang, O; Jang, BK; Kang, YG; Kim, DJ; Kim, JH; Kim, JW; Lee, J; Moon, MK; Park, KD; Song, HJ; Woo, SY; Yeon, SK, 2014)
"A murine lupus nephritis model using Nrf2(+/+) and Nrf2(-/-) mice was established using pristine injection."	1.40	Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response. ( Jiang, T; Lin, Y; Tian, F; Whitman, SA; Zhang, DD; Zhang, N; Zhang, Z; Zheng, H, 2014)
"Bronchial carcinoids are pulmonary neuroendocrine cell-derived tumors comprising typical (TC) and atypical (AC) malignant phenotypes."	1.39	Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines. ( Adeli, K; Cutz, E; Islam, SS; Kumar, S; Mokhtari, RB; Yazdanpanah, M; Yeger, H, 2013)
"Pancreatic cancer is a deadly disease killing 37,000 Americans each year."	1.39	A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. ( Grandhi, BK; Prabhu, S; Thakkar, A; Wang, J, 2013)
"Sulforaphane was administered (5 or 50 mg/kg, i."	1.38	Photothrombosis-induced infarction of the mouse cerebral cortex is not affected by the Nrf2-activator sulforaphane. ( Andersson, HC; Hou, L; Nilsson, Å; Nilsson, M; Pekna, M; Pekny, M; Porritt, MJ, 2012)
"In Keap1-kd fed an MCDD, steatohepatitis did not develop over the observation periods; however, in Nrf2-null fed an MCDD, the pathological state of the steatohepatitis was aggravated in terms of fatty change, inflammation, fibrosis and iron accumulation."	1.38	Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis. ( Harada, N; Hashimoto, E; Horie, M; Ishii, T; Itoh, K; Okada, K; Shoda, J; Sugimoto, H; Taguchi, K; Tokushige, K; Ueda, T; Utsunomiya, H; Warabi, E; Yamamoto, M, 2012)
"Multiple myeloma is a fatal disease characterized by clonal proliferation of plasma cells in the bone marrow."	1.37	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. ( Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Hideshima, T; Jakubikova, J; Kim, K; Klippel, S; Leiba, M; McMillin, DW; Mitsiades, CS; Nahar, S; Negri, J; Ooi, M; Richardson, PG; Sedlak, J, 2011)
"Treatment with sulforaphane inhibited an increase in the post-ischemic left ventricular end-diastolic pressure (LVEDP) and improved the post-ischemic left ventricular developed pressure (LVDP), +/-dP/dt, and coronary flow as compared with the untreated control hearts."	1.36	Sulforaphane protects ischemic injury of hearts through antioxidant pathway and mitochondrial K(ATP) channels. ( Chae, HJ; Chae, SW; Gao, S; Kim, DS; Kim, SH; Lee, GH; Park, BH; Piao, CS, 2010)
"In this study, we found that oral squamous cell carcinomas (OSCCs) in Korean patients have a high level of COX-2 expression when compared with normal mucosa."	1.35	Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model. ( Cho, NP; Cho, SD; Choi, IS; Choi, KH; Choi, SH; Han, HS; Jung, JY; Kim, HJ; Kong, G; Leem, DH; Moon, KS; Soh, Y, 2009)
"Markers of apoptosis, angiogenesis, and metastasis were measured by immunohistochemistry."	1.35	Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. ( Ganapathy, S; Shankar, S; Srivastava, RK, 2008)
"Sulforaphane is an isothiocyanate derived from cruciferous vegetables that has been linked to decreased risk of certain cancers."	1.35	Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer. ( Bowden, GT; Dickinson, SE; Melton, TF; Olson, ER; Saboda, K; Zhang, J, 2009)
"Treatment with sulforaphane, a dietary antioxidant, activated Nrf2 and suppressed p38-VCAM-1 signaling at the susceptible site in wild-type but not Nrf2(-/-) animals, indicating that it suppresses EC activation via Nrf2."	1.35	Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. ( Carlsen, H; Chaudhury, H; Cuhlmann, S; Edirisinghe, I; Evans, PC; Hamdulay, SS; Haskard, DO; Krams, R; Luong, le A; Mason, JC; Rahman, I; Van der Heiden, K; Zakkar, M, 2009)
"Sulforaphane pretreatment significantly limited lung RSV replication and virus-induced inflammation in Nrf2(+/+) but not in Nrf2(-/-) mice."	1.35	Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. ( Cho, HY; Imani, F; Kleeberger, SR; Melendi, GA; Miller-DeGraff, L; Polack, FP; Walters, D; Yamamoto, M, 2009)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (9.02)	29.6817
2010's	95 (71.43)	24.3611
2020's	26 (19.55)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
Randomized,Double-blind, Placebo-controlled, Efficacy and Safety Study of Sulforaphane in Patients With Prodromal to Mild Alzheimer's Disease[NCT04213391]				160 participants (Anticipated)	Interventional	2020-05-10	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Quinone reductase induction as a biomarker for cancer chemoprevention. Journal of natural products, 2006, Volume: 69, Issue:3 Topics: Animals; Anticarcinogenic Agents; Biomarkers; Chalcone; Chalcones; Disease Models, Animal; Enzyme In	2006
Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease. Nutrients, 2021, Jan-18, Volume: 13, Issue:1 Topics: Animals; Brassica; Diet; Disease Models, Animal; Humans; Isothiocyanates; Kidney Failure, Chronic; M	2021
Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease. International journal of molecular sciences, 2021, Mar-13, Volume: 22, Issue:6 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Cell Line, Tumor; Disease Models, Ani	2021
Isothiocyanates and Xenobiotic Detoxification. Molecular nutrition & food research, 2018, Volume: 62, Issue:18 Topics: Animals; Carcinogens; Cell Line, Tumor; Disease Models, Animal; DNA Damage; Epoxide Hydrolases; Gluc	2018
Sulforaphane and prostate cancer interception. Drug discovery today, 2014, Volume: 19, Issue:9 Topics: Animals; Anticarcinogenic Agents; Brassica; Diet; Disease Models, Animal; Disease Progression; Human	2014
Mechanisms of estrogen carcinogenesis: The role of E2/E1-quinone metabolites suggests new approaches to preventive intervention--A review. Steroids, 2015, Volume: 99, Issue:Pt A Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinogens; Disease Models, Animal; Estradiol;	2015
Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases? Current topics in medicinal chemistry, 2015, Volume: 15, Issue:21 Topics: Animals; Autophagy; Disease Models, Animal; Food; Humans; Isothiocyanates; Lithium; Neurodegenerativ	2015
Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician's Expectation Be Matched by the Reality? Oxidative medicine and cellular longevity, 2016, Volume: 2016 Topics: Animals; Anticarcinogenic Agents; Area Under Curve; Brassica; Chemoprevention; Curcumin; Disease Mod	2016
Targeting cancer stem-like cells using dietary-derived agents - Where are we now? Molecular nutrition & food research, 2016, Volume: 60, Issue:6 Topics: Animals; Anticarcinogenic Agents; Catechin; Cell Line, Tumor; Curcumin; Diet; Disease Models, Animal	2016
Nutritional Epigenetics and the Prevention of Hepatocellular Carcinoma with Bioactive Food Constituents. Nutrition and cancer, 2016, Volume: 68, Issue:5 Topics: Animals; Butyric Acid; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Curcumin; Disease Mode	2016

Article	Year
Potential cancer chemopreventive constituents of the seeds of Dipteryx odorata (tonka bean). Journal of natural products, 2003, Volume: 66, Issue:5 Topics: Animals; Anticarcinogenic Agents; Crystallography, X-Ray; Disease Models, Animal; Diterpenes; Drug S	2003
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological	2010
Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson's disease therapy. Journal of medicinal chemistry, 2014, Feb-27, Volume: 57, Issue:4 Topics: Animals; Base Sequence; Cell Line; Disease Models, Animal; DNA Primers; Heme Oxygenase-1; Humans; Ma	2014
Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy. Journal of medicinal chemistry, 2019, 01-24, Volume: 62, Issue:2 Topics: Animals; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Glutamate-Cysteine Ligase; Heme Ox	2019
A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model. European journal of medicinal chemistry, 2020, Jan-01, Volume: 185 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Chalcone; Disease	2020
Dietary Isothiocyanates, Sulforaphane and 2-Phenethyl Isothiocyanate, Effectively Impair International journal of molecular sciences, 2021, Sep-22, Volume: 22, Issue:19 Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Line; Chlorocebus aethiops; Cholera; Disease Models,	2021
Targeting Oxidative Stress with Antioxidant Duotherapy after Experimental Traumatic Brain Injury. International journal of molecular sciences, 2021, Sep-29, Volume: 22, Issue:19 Topics: Acetylcysteine; Animals; Antioxidants; Brain; Brain Injuries, Traumatic; Cell Line; Cell Survival; C	2021
Attenuation of experimentally induced atopic dermatitis in mice by sulforaphane: effect on inflammation and apoptosis. Toxicology mechanisms and methods, 2022, Volume: 32, Issue:3 Topics: Animals; Apoptosis; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Inflammation; Isothiocyan	2022
mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma. Molecular biology reports, 2022, Volume: 49, Issue:1 Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Esophageal Neoplasms; Humans; Imm	2022
Sulforaphane improves cognitive dysfunction after surgery and anesthesia in mice: The role of Keap1-Nrf2 signaling. Brain research bulletin, 2022, Volume: 181 Topics: Anesthesia, General; Animals; Behavior, Animal; Disease Models, Animal; Hippocampus; Isothiocyanates	2022
The Protective Effect of Sulforaphane on ER-induced Apoptosis and Inflammation in Necrotizing Enterocolitis Mice. Combinatorial chemistry & high throughput screening, 2023, Volume: 26, Issue:6 Topics: Animals; Apoptosis; Disease Models, Animal; Enterocolitis, Necrotizing; Inflammation; Interleukin-10	2023
An experimental evaluation of the efficacy of perinatal sulforaphane supplementation to decrease the incidence and severity of vinclozolin-induced hypospadias in the mouse model. Toxicology and applied pharmacology, 2022, 09-15, Volume: 451 Topics: Animals; Dietary Supplements; Disease Models, Animal; Environmental Pollutants; Female; Humans; Hypo	2022
Therapeutic effect of the sulforaphane derivative JY4 on ulcerative colitis through the NF-κB-p65 pathway. Inflammopharmacology, 2022, Volume: 30, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Mod	2022
Broccoli seed extract rich in polysaccharides and glucoraphanin ameliorates DSS-induced colitis via intestinal barrier protection and gut microbiota modulation in mice. Journal of the science of food and agriculture, 2023, Mar-15, Volume: 103, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Brassica; Colitis; Colon; Dextran Sulfate; Disease Models, Animal	2023
Broccoli seed extract rich in polysaccharides and glucoraphanin ameliorates DSS-induced colitis via intestinal barrier protection and gut microbiota modulation in mice. Journal of the science of food and agriculture, 2023, Mar-15, Volume: 103, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Brassica; Colitis; Colon; Dextran Sulfate; Disease Models, Animal	2023
Broccoli seed extract rich in polysaccharides and glucoraphanin ameliorates DSS-induced colitis via intestinal barrier protection and gut microbiota modulation in mice. Journal of the science of food and agriculture, 2023, Mar-15, Volume: 103, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Brassica; Colitis; Colon; Dextran Sulfate; Disease Models, Animal	2023
Broccoli seed extract rich in polysaccharides and glucoraphanin ameliorates DSS-induced colitis via intestinal barrier protection and gut microbiota modulation in mice. Journal of the science of food and agriculture, 2023, Mar-15, Volume: 103, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Brassica; Colitis; Colon; Dextran Sulfate; Disease Models, Animal	2023
Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling. Cell death & disease, 2023, Nov-25, Volume: 14, Issue:11 Topics: Animals; Antioxidants; Cytokines; Disease Models, Animal; Humans; Inflammation; Kelch-Like ECH-Assoc	2023
Dietary supplementation with sulforaphane attenuates liver damage and heme overload in a sickle cell disease murine model. Experimental hematology, 2019, Volume: 77 Topics: Anemia, Sickle Cell; Animals; Dietary Supplements; Disease Models, Animal; Female; Heme; Humans; Iso	2019
Anti-nociceptive and anti-inflammatory effects of sulforaphane on sciatic endometriosis in a rat model. Neuroscience letters, 2020, 04-01, Volume: 723 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Dose-Response Relationship, D	2020
Activating PPARγ Increases NQO1 and γ-GCS Expression via Nrf2 in Thrombin-activated Microglia. Current medical science, 2020, Volume: 40, Issue:1 Topics: Animals; Animals, Newborn; Cells, Cultured; Cerebral Hemorrhage; Disease Models, Animal; Female; Glu	2020
The Role of Lysosome-associated Membrane Protein 2 in Prostate Cancer Chemopreventive Mechanisms of Sulforaphane. Cancer prevention research (Philadelphia, Pa.), 2020, Volume: 13, Issue:8 Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Disease Mo	2020
Sulforaphane and Vitamin E Protect From Glucotoxic Neurodegeneration and Lifespan Reduction In C. Elegans. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2021, Volume: 129, Issue:12 Topics: Animals; Antioxidants; Caenorhabditis elegans; Disease Models, Animal; Drug Therapy, Combination; Gl	2021
Treatment of dilated cardiomyopathy in a mouse model of Friedreich's ataxia using N-acetylcysteine and identification of alterations in microRNA expression that could be involved in its pathogenesis. Pharmacological research, 2020, Volume: 159 Topics: Acetylcysteine; Animals; Basic-Leucine Zipper Transcription Factors; Cardiomyopathy, Dilated; Cell L	2020
Investigation of molecular mechanisms of experimental compounds in murine models of chronic allergic airways disease using synchrotron Fourier-transform infrared microspectroscopy. Scientific reports, 2020, 07-16, Volume: 10, Issue:1 Topics: Animals; Anti-Asthmatic Agents; Asthma; Chronic Disease; Disease Models, Animal; Drug Evaluation, Pr	2020
Sulforaphane Elicits Protective Effects in Intestinal Ischemia Reperfusion Injury. International journal of molecular sciences, 2020, Jul-22, Volume: 21, Issue:15 Topics: Animals; Blood Platelets; Disease Models, Animal; Intestinal Mucosa; Isothiocyanates; Leukocytes; Ma	2020
Sulforaphane delays diabetes-induced retinal photoreceptor cell degeneration. Cell and tissue research, 2020, Volume: 382, Issue:3 Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Endoplasmic	2020
Sulforaphane Reverses the Amyloid-β Oligomers Induced Depressive-Like Behavior. Journal of Alzheimer's disease : JAD, 2020, Volume: 78, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Brain; Depression; Disease Models,	2020
Neuroprotective potential of isothiocyanates in an in vitro model of neuroinflammation. Inflammopharmacology, 2021, Volume: 29, Issue:2 Topics: Animals; Astrocytes; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Fema	2021
Sulforaphane and Albumin Attenuate Experimental Intestinal Ischemia-Reperfusion Injury. The Journal of surgical research, 2021, Volume: 262 Topics: Albumins; Animals; Antioxidants; Disease Models, Animal; Intestines; Isothiocyanates; Male; NF-kappa	2021
Nrf2 Activation Attenuates Acrylamide-Induced Neuropathy in Mice. International journal of molecular sciences, 2021, Jun-01, Volume: 22, Issue:11 Topics: Acrylamide; Animals; Disease Models, Animal; Humans; Inflammation; Isothiocyanates; Mice; Microglia;	2021
Sulforaphane alleviates hyperalgesia and enhances analgesic potency of morphine in rats with cancer-induced bone pain. European journal of pharmacology, 2021, Oct-15, Volume: 909 Topics: Animals; Bone Neoplasms; Cancer Pain; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Drug	2021
Sulforaphane prevents bleomycin‑induced pulmonary fibrosis in mice by inhibiting oxidative stress via nuclear factor erythroid 2‑related factor‑2 activation. Molecular medicine reports, 2017, Volume: 15, Issue:6 Topics: Alveolar Epithelial Cells; Animals; Apoptosis; Bleomycin; Disease Models, Animal; Gene Expression; I	2017
Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity. Molecular therapy : the journal of the American Society of Gene Therapy, 2017, 08-02, Volume: 25, Issue:8 Topics: Animals; Antineoplastic Agents; Antioxidants; Autophagy; Cell Line; Combined Modality Therapy; Disea	2017
Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. Brain : a journal of neurology, 2017, Jul-01, Volume: 140, Issue:7 Topics: Acetylcysteine; Animals; Astrocytes; Biomarkers; Cognitive Dysfunction; Disease Models, Animal; Drug	2017
Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation. Cardiovascular therapeutics, 2017, Volume: 35, Issue:5 Topics: Animals; Cardiotoxicity; Cell Line; Chronic Disease; Collagen; Disease Models, Animal; Doxorubicin;	2017
Sulforaphane Reduces HMGB1-Mediated Septic Responses and Improves Survival Rate in Septic Mice. The American journal of Chinese medicine, 2017, Volume: 45, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Brassicaceae; Cell Movement; Disease Models, Animal; HMGB1 Protei	2017
Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression. Scientific reports, 2017, 08-24, Volume: 7, Issue:1 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Catechin; Cell Line, Tumor; Disease Mode	2017
Protective effect of sulforaphane against retinal degeneration in the Pde6 Current eye research, 2017, Volume: 42, Issue:12 Topics: Animals; Animals, Newborn; Antioxidants; Apoptosis; Blotting, Western; Cell Survival; Cyclic Nucleot	2017
The Sulforaphane and pyridoxamine supplementation normalize endothelial dysfunction associated with type 2 diabetes. Scientific reports, 2017, 10-30, Volume: 7, Issue:1 Topics: Animals; Aorta; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Endothelium;	2017
Sexual Dimorphism in Response to an NRF2 Inducer in a Model for Pachyonychia Congenita. The Journal of investigative dermatology, 2018, Volume: 138, Issue:5 Topics: Animals; Disease Models, Animal; Estrogen Receptor alpha; Female; Glutathione; Humans; Isothiocyanat	2018
Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. Rheumatology (Oxford, England), 2018, 04-01, Volume: 57, Issue:4 Topics: Acute Disease; Administration, Oral; Animals; Anticarcinogenic Agents; Cells, Cultured; Disease Mode	2018
Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway. Redox biology, 2018, Volume: 15 Topics: Angiotensin II; Animals; Diabetic Cardiomyopathies; Disease Models, Animal; Glycogen Synthase Kinase	2018
Nrf2 antioxidant pathway suppresses Numb-mediated epithelial-mesenchymal transition during pulmonary fibrosis. Cell death & disease, 2018, 01-23, Volume: 9, Issue:2 Topics: Animals; Antioxidants; Bleomycin; Cell Line; Disease Models, Animal; Down-Regulation; Epithelial-Mes	2018
Sulforaphane Modulates Joint Inflammation in a Murine Model of Complete Freund's Adjuvant-Induced Mono-Arthritis. Molecules (Basel, Switzerland), 2018, 04-24, Volume: 23, Issue:5 Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Biomarkers; Cytokines; Disease Models, Anim	2018
Sulforaphane Upregulates the Heat Shock Protein Co-Chaperone CHIP and Clears Amyloid-β and Tau in a Mouse Model of Alzheimer's Disease. Molecular nutrition & food research, 2018, Volume: 62, Issue:12 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Disease Models, Animal; Female;	2018
Lightly Cooked Broccoli Is as Effective as Raw Broccoli in Mitigating Dextran Sulfate Sodium-Induced Colitis in Mice. Nutrients, 2018, Jun-08, Volume: 10, Issue:6 Topics: Animals; Brassica; Colitis; Colon; Cooking; Dextran Sulfate; Disease Models, Animal; Enzyme Stabilit	2018
Sulforaphane ameliorates steroid insensitivity through an Nrf2-dependent pathway in cigarette smoke-exposed asthmatic mice. Free radical biology & medicine, 2018, Volume: 129 Topics: Animals; Anti-Asthmatic Agents; Asthma; Dexamethasone; Disease Models, Animal; Drug Combinations; Fe	2018
Antitumor activity of sulforaphane in mice model of skin cancer via blocking sulfatase-2. Experimental dermatology, 2019, Volume: 28, Issue:1 Topics: Animals; Anthracenes; Anticarcinogenic Agents; Antioxidants; Apoptosis; Carcinogens; Caspase 3; Dise	2019
Sulforaphane enriched transcriptome of lung mitochondrial energy metabolism and provided pulmonary injury protection via Nrf2 in mice. Toxicology and applied pharmacology, 2019, 02-01, Volume: 364 Topics: Acute Lung Injury; Animals; Antioxidant Response Elements; Antioxidants; Disease Models, Animal; DNA	2019
Nrf2 activator, sulforaphane ameliorates autism-like symptoms through suppression of Th17 related signaling and rectification of oxidant-antioxidant imbalance in periphery and brain of BTBR T+tf/J mice. Behavioural brain research, 2019, 05-17, Volume: 364 Topics: Animals; Antioxidants; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Brain; Cytokin	2019
Nrf2 activation via Keap1 deletion or sulforaphane treatment reduces Ova-induced sinonasal inflammation. Allergy, 2019, Volume: 74, Issue:9 Topics: Allergens; Animals; Disease Models, Animal; Disease Susceptibility; Humans; Isothiocyanates; Kelch-L	2019
SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis. Multiple sclerosis and related disorders, 2019, Volume: 30 Topics: Animals; Anticarcinogenic Agents; Disability Evaluation; Disease Models, Animal; Dose-Response Relat	2019
Sulforaphane treatment reverses corticosteroid resistance in a mixed granulocytic mouse model of asthma by upregulation of antioxidants and attenuation of Th17 immune responses in the airways. European journal of pharmacology, 2019, Jul-15, Volume: 855 Topics: Adrenal Cortex Hormones; Animals; Antioxidants; Asthma; Cytokines; Disease Models, Animal; Drug Resi	2019
Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. Brain : a journal of neurology, 2019, 07-01, Volume: 142, Issue:7 Topics: Acetylcysteine; Animals; Astrocytes; Biomarkers; Case-Control Studies; Cell Count; Cognitive Dysfunc	2019
Sulforaphane has a therapeutic effect in an atopic dermatitis murine model and activates the Nrf2/HO‑1 axis. Molecular medicine reports, 2019, Volume: 20, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Dermatitis, Atopic; Disease Models, Animal; Female;	2019
Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease. Neurotoxicology, 2013, Volume: 36 Topics: Actinin; Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Caspase 3; Disease Models, A	2013
Epigallocatechin-3-gallate is a potent phytochemical inhibitor of intimal hyperplasia in the wire-injured carotid artery. Journal of vascular surgery, 2013, Volume: 58, Issue:5 Topics: Animals; Cardiovascular Agents; Carotid Artery Injuries; Carotid Artery, Common; Carotid Intima-Medi	2013
Sulforaphane can protect lens cells against oxidative stress: implications for cataract prevention. Investigative ophthalmology & visual science, 2013, Aug-05, Volume: 54, Issue:8 Topics: Animals; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Cataract; Cell Proliferation; Cells,	2013
Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines. BMC cancer, 2013, Aug-08, Volume: 13 Topics: Acetazolamide; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carbonic Anhydrase Inhibitors; C	2013
Sulforaphane inhibits mammary adipogenesis by targeting adipose mesenchymal stem cells. Breast cancer research and treatment, 2013, Volume: 141, Issue:2 Topics: Adipocytes; Adipogenesis; Animals; Breast Neoplasms; Cell Communication; Cell Differentiation; Cell	2013
Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response. Kidney international, 2014, Volume: 85, Issue:2 Topics: Adult; Animals; Antibodies, Monoclonal; Case-Control Studies; Cells, Cultured; Disease Models, Anima	2014
A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer prevention research (Philadelphia, Pa.), 2013, Volume: 6, Issue:10 Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot	2013
Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease. Journal of neurochemistry, 2014, Volume: 129, Issue:3 Topics: Animals; Autophagy; Blotting, Western; Disease Models, Animal; HEK293 Cells; HeLa Cells; Humans; Hun	2014
Sulforaphane pretreatment prevents systemic inflammation and renal injury in response to cardiopulmonary bypass. The Journal of thoracic and cardiovascular surgery, 2014, Volume: 148, Issue:2 Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Cardiopulmonary Bypass; Cells, Cultured; Dis	2014
Sulforaphane inhibits endothelial protein C receptor shedding in vitro and in vivo. Vascular pharmacology, 2014, Volume: 63, Issue:1 Topics: ADAM Proteins; ADAM17 Protein; Animals; Blood Coagulation Factors; Cecum; Disease Models, Animal; Hu	2014
Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid β deposits and peroxidation in mice with Alzheimer-like lesions. American journal of Alzheimer's disease and other dementias, 2015, Volume: 30, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Cerebral Cortex; Disease Models	2015
Sulforaphane protects rodent retinas against ischemia-reperfusion injury through the activation of the Nrf2/HO-1 antioxidant pathway. PloS one, 2014, Volume: 9, Issue:12 Topics: Amacrine Cells; Animals; Antioxidants; Apoptosis; Disease Models, Animal; Heme Oxygenase-1; Inflamma	2014
Sulforaphane reduces apoptosis and oncosis along with protecting liver injury-induced ischemic reperfusion by activating the Nrf2/ARE pathway. Hepatology international, 2015, Volume: 9, Issue:2 Topics: Alanine Transaminase; Animals; Anticarcinogenic Agents; Apoptosis; Aspartate Aminotransferases; Calc	2015
The effects of sulforaphane on the liver and remote organ damage in hepatic ischemia-reperfusion model formed with pringle maneuver in rats. International journal of surgery (London, England), 2015, Volume: 18 Topics: Animals; Anticarcinogenic Agents; Disease Models, Animal; Drug Administration Schedule; Ischemia; Is	2015
Dietary Intake of Sulforaphane-Rich Broccoli Sprout Extracts during Juvenile and Adolescence Can Prevent Phencyclidine-Induced Cognitive Deficits at Adulthood. PloS one, 2015, Volume: 10, Issue:6 Topics: Adolescent; Adult; Animals; Brassica; Child; Cognition Disorders; Disease Models, Animal; Hippocampu	2015
Sulforaphane rescues memory dysfunction and synaptic and mitochondrial alterations induced by brain iron accumulation. Neuroscience, 2015, Aug-20, Volume: 301 Topics: Animals; Animals, Newborn; Anticarcinogenic Agents; Brain; Catalase; Disease Models, Animal; Dynamin	2015
Protection of retinal function by sulforaphane following retinal ischemic injury. Experimental eye research, 2015, Volume: 138 Topics: Animals; Disease Models, Animal; Electroretinography; Injections, Intraperitoneal; Isothiocyanates;	2015
Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. Journal of leukocyte biology, 2016, Volume: 99, Issue:1 Topics: Animals; Biological Transport; Carrier Proteins; Caspase 1; Cell Line; Cell Membrane; Disease Models	2016
Sulforaphane is anticonvulsant and improves mitochondrial function. Journal of neurochemistry, 2015, Volume: 135, Issue:5 Topics: Animals; Anticonvulsants; Convulsants; Disease Models, Animal; Electron Transport Complex I; Electro	2015
Mechanisms underlying the perifocal neuroprotective effect of the Nrf2-ARE signaling pathway after intracranial hemorrhage. Drug design, development and therapy, 2015, Volume: 9 Topics: Animals; Antioxidant Response Elements; Blotting, Western; Cerebral Hemorrhage; Dimethyl Sulfoxide;	2015
Sulforaphane reduces lipopolysaccharide-induced proinflammatory markers in hippocampus and liver but does not improve sickness behavior. Nutritional neuroscience, 2017, Volume: 20, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antioxidant Response Elem	2017
Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice. Behavioural brain research, 2016, Mar-15, Volume: 301 Topics: Adrenocorticotropic Hormone; Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents; Antidepressive	2016
Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction. Journal of the Formosan Medical Association = Taiwan yi zhi, 2017, Volume: 116, Issue:1 Topics: Aldehyde Dehydrogenase 1 Family; Animals; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Cell Li	2017
Hyperammonemia induces glial activation, neuroinflammation and alters neurotransmitter receptors in hippocampus, impairing spatial learning: reversal by sulforaphane. Journal of neuroinflammation, 2016, Feb-16, Volume: 13 Topics: Animals; Anti-Inflammatory Agents; Body Weight; Cytokines; Disease Models, Animal; Encephalitis; Gen	2016
Sulforaphane promotes murine hair growth by accelerating the degradation of dihydrotestosterone. Biochemical and biophysical research communications, 2016, Mar-25, Volume: 472, Issue:1 Topics: 3-Hydroxysteroid Dehydrogenases; Alopecia; Animals; Cell Line; Dihydrotestosterone; Disease Models,	2016
A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Scientific reports, 2016, Apr-14, Volume: 6 Topics: Administration, Oral; Animals; Diet, High-Fat; Disease Models, Animal; Enzyme Inhibitors; Inflammaso	2016
Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia. Journal of neuroinflammation, 2016, Apr-18, Volume: 13, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Cell Membrane; Cerebellum; Disease Models, Ani	2016
Glutathione antioxidant pathway activity and reserve determine toxicity and specificity of the biliary toxin biliatresone in zebrafish. Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:3 Topics: Acetylcysteine; Animals; Animals, Genetically Modified; Benzodioxoles; Biliary Atresia; Disease Mode	2016
Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes. The Journal of clinical investigation, 2016, 06-01, Volume: 126, Issue:6 Topics: Animals; Disease Models, Animal; Glutathione; Humans; Isothiocyanates; Keratin-16; Keratoderma, Palm	2016
Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2016, Volume: 26, Issue:9 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta; Aortitis; Cell Adhesion Molecules; Cell Line	2016
Nuclear factor erythroid 2-related factor 2 is a critical target for the treatment of glucocorticoid-resistant lupus nephritis. Arthritis research & therapy, 2016, 06-14, Volume: 18, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Dimethyl Fumarate; Disease Models, Animal; Drug Resistance; Enzym	2016
Sulforaphane induces neurovascular protection against a systemic inflammatory challenge via both Nrf2-dependent and independent pathways. Vascular pharmacology, 2016, Volume: 85 Topics: Adolescent; Adult; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Cell Line; Disease Models	2016
Sulforaphane Ameliorates Bladder Dysfunction through Activation of the Nrf2-ARE Pathway in a Rat Model of Partial Bladder Outlet Obstruction. Oxidative medicine and cellular longevity, 2016, Volume: 2016 Topics: Animals; Antioxidant Response Elements; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Catalas	2016
Broccoli sprout extract prevents diabetic cardiomyopathy via Nrf2 activation in db/db T2DM mice. Scientific reports, 2016, 07-26, Volume: 6 Topics: Animals; Brassica; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Gen	2016
Sulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways. Scientific reports, 2016, 08-24, Volume: 6 Topics: Animals; Autophagy; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Glutathione; Humans; Is	2016
Sulforaphane activates the cerebral vascular Nrf2-ARE pathway and suppresses inflammation to attenuate cerebral vasospasm in rat with subarachnoid hemorrhage. Brain research, 2016, 12-15, Volume: 1653 Topics: Animals; Appetite; Basilar Artery; Carboxylic Ester Hydrolases; Cytokines; Disease Models, Animal; D	2016
Sulforaphane Prevents Testicular Damage in Kunming Mice Exposed to Cadmium via Activation of Nrf2/ARE Signaling Pathways. International journal of molecular sciences, 2016, Oct-11, Volume: 17, Issue:10 Topics: Animals; Anticarcinogenic Agents; Antioxidant Response Elements; Body Weight; Cadmium; Disease Model	2016
Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways. Molecular nutrition & food research, 2017, Volume: 61, Issue:2 Topics: Alzheimer Disease; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral Cortex; Dis	2017
Sulforaphane Improves Ischemia-Induced Detrusor Overactivity by Downregulating the Enhancement of Associated Endoplasmic Reticulum Stress, Autophagy, and Apoptosis in Rat Bladder. Scientific reports, 2016, 11-08, Volume: 6 Topics: Animals; Apoptosis; Atherosclerosis; Autophagy; Disease Models, Animal; Endoplasmic Reticulum Stress	2016
Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation. The Journal of nutritional biochemistry, 2017, Volume: 39 Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Brassica; Depression; Disease Models,	2017
Sulforaphane protects against sodium valproate-induced acute liver injury. Canadian journal of physiology and pharmacology, 2017, Volume: 95, Issue:4 Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Anticonvulsants; A	2017
Sulforaphane Prevents Angiotensin II-Induced Testicular Cell Death via Activation of NRF2. Oxidative medicine and cellular longevity, 2017, Volume: 2017 Topics: Angiotensin II; Animals; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Disease Models, Anim	2017
Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase. Molecular therapy : the journal of the American Society of Gene Therapy, 2017, 07-05, Volume: 25, Issue:7 Topics: Administration, Oral; Adoptive Transfer; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory A	2017
Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model. Oral oncology, 2009, Volume: 45, Issue:8 Topics: Animals; Anticarcinogenic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspases; Cyclooxygenase 2 In	2009
Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. American journal of respiratory and critical care medicine, 2009, Jan-15, Volume: 179, Issue:2 Topics: Animals; Anticarcinogenic Agents; Bronchoalveolar Lavage Fluid; Buffers; Disease Models, Animal; Dru	2009
Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21 Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Drug Synergism; Isothiocyanates; Mal	2008
Sulforaphane improves cognitive function administered following traumatic brain injury. Neuroscience letters, 2009, Aug-28, Volume: 460, Issue:2 Topics: Aldehydes; Animals; Anticarcinogenic Agents; Brain Injuries; Cognition Disorders; Disease Models, An	2009
Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer. Cancer research, 2009, Sep-01, Volume: 69, Issue:17 Topics: Animals; Anticarcinogenic Agents; Binding Sites; Carcinoma, Squamous Cell; Cysteine; Disease Models,	2009
Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:11 Topics: Animals; Arteries; Arteritis; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Enzyme Act	2009
Sulforaphane protects ischemic injury of hearts through antioxidant pathway and mitochondrial K(ATP) channels. Pharmacological research, 2010, Volume: 61, Issue:4 Topics: Animals; Antioxidants; Atrial Natriuretic Factor; bcl-2-Associated X Protein; Caspase 3; Decanoic Ac	2010
Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme. Brain research, 2010, Jul-09, Volume: 1343 Topics: Animals; Animals, Newborn; Apoptosis; Biomarkers; Disease Models, Animal; Enzyme Induction; Heme Oxy	2010
The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer. Molecular cancer, 2010, Jul-13, Volume: 9 Topics: Alternative Splicing; Animals; Apoptosis; Cell Cycle; Diet; Disease Models, Animal; Gene Deletion; G	2010
The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice. Acta pharmacologica Sinica, 2010, Volume: 31, Issue:11 Topics: Animals; Antioxidants; Blotting, Western; Brain; Brain Injuries; Cell Death; Disease Models, Animal;	2010
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica, 2011, Volume: 96, Issue:8 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line; Cell Proliferation; Cell Survival;	2011
Impaired integrity of DNA after recovery from inflammation causes persistent dysfunction of colonic smooth muscle. Gastroenterology, 2011, Volume: 141, Issue:4 Topics: Acetylcholine; Animals; Calcium Channels, L-Type; Colitis; Colon; Disease Models, Animal; DNA Damage	2011
Activation of the nuclear factor E2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury. Journal of neurotrauma, 2012, Mar-20, Volume: 29, Issue:5 Topics: Animals; Disease Models, Animal; Female; Immunoblotting; Immunohistochemistry; Isothiocyanates; Moto	2012
Nrf2 and NF-κB modulation by sulforaphane counteracts multiple manifestations of diabetic neuropathy in rats and high glucose-induced changes. Current neurovascular research, 2011, Volume: 8, Issue:4 Topics: Animals; Blood Glucose; Body Weight; Cell Line, Transformed; Diabetic Neuropathies; Disease Models,	2011
Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis. Journal of gastroenterology, 2012, Volume: 47, Issue:8 Topics: Adaptor Proteins, Signal Transducing; Animals; Anticarcinogenic Agents; Choline Deficiency; Cytoskel	2012
Sulforaphane inhibits the Th2 immune response in ovalbumin-induced asthma. BMB reports, 2012, Volume: 45, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dow	2012
Neuroprotective effects of sulforaphane after contusive spinal cord injury. Journal of neurotrauma, 2012, Nov-01, Volume: 29, Issue:16 Topics: Animals; Antioxidants; Chromatography, High Pressure Liquid; Disease Models, Animal; Female; Gene Ex	2012
Photothrombosis-induced infarction of the mouse cerebral cortex is not affected by the Nrf2-activator sulforaphane. PloS one, 2012, Volume: 7, Issue:7 Topics: Animals; Cerebral Infarction; Disease Models, Animal; Gene Expression Regulation; Gliosis; Isothiocy	2012
Sulforaphane protects small intestinal mucosa from aspirin/NSAID-induced injury by enhancing host defense systems against oxidative stress and by inhibiting mucosal invasion of anaerobic enterobacteria. Current pharmaceutical design, 2013, Volume: 19, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Capillary Permeability; Cel	2013
Biochemistry: A radical treatment. Nature, 2012, Sep-27, Volume: 489, Issue:7417 Topics: Animals; Antioxidants; Clinical Trials as Topic; Disease Models, Animal; Free Radicals; Humans; Isot	2012
Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxidative medicine and cellular longevity, 2012, Volume: 2012 Topics: Animals; Anticarcinogenic Agents; Catalase; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nep	2012
Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2013, Volume: 20, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Avoidance Learning; Cell Line; Cogn	2013
Sulforaphane enhances aquaporin-4 expression and decreases cerebral edema following traumatic brain injury. Journal of neuroscience research, 2005, Nov-15, Volume: 82, Issue:4 Topics: Animals; Aquaporin 4; Blotting, Northern; Body Water; Brain Edema; Brain Injuries; Cell Count; Disea	2005
Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neuroscience letters, 2006, Jan-30, Volume: 393, Issue:2-3 Topics: Analysis of Variance; Animals; Blotting, Northern; Brain Infarction; Brain Ischemia; Disease Models,	2006
Delay of photoreceptor degeneration in tubby mouse by sulforaphane. Journal of neurochemistry, 2007, Volume: 101, Issue:4 Topics: Adaptor Proteins, Signal Transducing; Age Factors; Animals; Animals, Newborn; Disease Models, Animal	2007
Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Jan-09, Volume: 28, Issue:2 Topics: Age Factors; Allyl Compounds; alpha-Synuclein; Animals; Animals, Genetically Modified; Cell Death; D	2008

sulforaphane and Disease Models, Animal

Research Excerpts

Research

Studies (133)

Authors

Clinical Trials (1)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Jang, DS	1
Park, EJ	1
Hawthorne, ME	1
Vigo, JS	1
Graham, JG	1
Cabieses, F	1
Santarsiero, BD	1
Mesecar, AD	1
Fong, HH	1
Mehta, RG	1
Pezzuto, JM	2
Kinghorn, AD	1
Cuendet, M	1
Oteham, CP	1
Moon, RC	1
Avdeef, A	1
Tam, KY	1
Woo, SY	2
Kim, JH	1
Moon, MK	1
Han, SH	1
Yeon, SK	1
Choi, JW	3
Jang, BK	2
Song, HJ	1
Kang, YG	1
Kim, JW	3
Lee, J	2
Kim, DJ	2
Hwang, O	1
Park, KD	3
Kim, S	1
Park, JH	4
Kim, HJ	3
Shin, SJ	1
Lee, C	1
Han, SM	1
Pae, AN	2
Han, G	1
Park, SJ	1
Byeon, SR	1
Lee, YS	1
Cheong, E	1
Krause, K	1
Pyrczak-Felczykowska, A	1
Karczewska, M	1
Narajczyk, M	1
Herman-Antosiewicz, A	1
Szalewska-Pałasz, A	1
Nowicki, D	1
Kyyriäinen, J	1
Kajevu, N	1
Bañuelos, I	1
Lara, L	1
Lipponen, A	1
Balosso, S	3
Hämäläinen, E	1
Das Gupta, S	1
Puhakka, N	1
Natunen, T	1
Ravizza, T	3
Vezzani, A	3
Hiltunen, M	1
Pitkänen, A	1
Alyoussef, A	2
Lu, Z	1
Zhang, Y	3
Xu, Y	1
Wei, H	1
Zhao, W	1
Wang, P	1
Li, Y	2
Hou, G	1
Hua, D	1
Luo, A	1
Wu, Z	1
Huang, C	1
Li, S	1
Xu, X	1
Xu, J	1
Yang, C	3
Wang, D	2
Liu, C	2
Wang, X	7
Mi, Y	1
Xiong, X	1
Bao, Z	1
Amato, CM	1
Fricke, A	1
Marella, S	1
Mogus, JP	1
Bereman, M	1
McCoy, KA	1
Zhao, XJ	1
Zhang, YR	1
Bai, WF	1
Sun, TY	1
Yang, YF	1
Wang, TX	1
Bai, CG	1
Wu, J	3
Guo, W	2
Cui, S	2
Tang, X	2
Zhang, Q	2
Lu, W	3
Jin, Y	3
Zhao, J	5
Mao, B	2
Chen, W	2
Ma, C	1
Gu, C	1
Lian, P	1
Wazir, J	1
Lu, R	1
Ruan, B	1
Wei, L	2
Li, L	3
Pu, W	1
Peng, Z	1
Wang, W	2
Zong, Y	1
Huang, Z	2
Wang, H	3
Lu, Y	1
Su, Z	1
Panda, H	1
Keleku-Lukwete, N	1
Kuga, A	1
Fuke, N	1
Suganuma, H	4
Suzuki, M	1
Yamamoto, M	5
Liu, Y	3
Zhang, Z	4
Lu, X	2
Meng, J	1
Qin, X	1
Jiang, J	1
Hang, H	1
Wang, LK	1
Ren, SY	1
Song, AJ	1
Wu, GF	1
Hahm, ER	1
Singh, KB	1
Kim, SH	2
Powolny, AA	1
Singh, SV	1
Schlotterer, A	1
Masri, B	1
Humpert, M	1
Krämer, BK	1
Hammes, HP	1
Morcos, M	1
Chiang, S	1
Huang, MLH	1
Richardson, DR	1
Mazarakis, N	1
Vongsvivut, J	1
Bambery, KR	1
Ververis, K	1
Tobin, MJ	1
Royce, SG	1
Samuel, CS	1
Snibson, KJ	1
Licciardi, PV	1
Karagiannis, TC	1
Chen, Z	1
Mohr, A	1
Heitplatz, B	1
Hansen, U	1
Pascher, A	1
Brockmann, JG	1
Becker, F	2
Lv, J	1
Bao, S	1
Liu, T	1
Ye, W	1
Wang, N	1
Song, S	1
Li, J	1
Chudhary, M	1
Ren, X	1
Kong, L	3
Wei, C	1
Quan, M	1
Li, T	1
Jia, J	1
Latronico, T	1
Larocca, M	1
Milella, S	1
Fasano, A	1
Rossano, R	1
Liuzzi, GM	1
Liebman, SE	1
Le, TH	1
Sampaio de Holanda, G	1
Dos Santos Valença, S	1
Maran Carra, A	1
Lopes Lichtenberger, RC	1
Franco, OB	1
Ribeiro, BE	1
Bittencourt Rosas, SL	1
Santana, PT	1
Lima Castelo-Branco, MT	1
Pereira de Souza, HS	1
Schanaider, A	1
Kim, J	5
Davuljigari, CB	1
Ekuban, FA	1
Zong, C	1
Fergany, AAM	1
Morikawa, K	1
Ichihara, G	1
Fu, J	1
Xu, M	1
Xu, L	2
Ni, H	1
Zhao, B	1
Ni, C	1
Huang, M	1
Zhu, J	1
Luo, G	1
Yao, M	1
Yan, B	1
Ma, Z	1
Shi, S	1
Hu, Y	1
Ma, T	1
Rong, G	1
Yang, J	3
Olagnier, D	1
Lababidi, RR	1
Hadj, SB	1
Sze, A	1
Naidu, SD	1
Ferrari, M	1
Jiang, Y	1
Chiang, C	1
Beljanski, V	1
Goulet, ML	1
Knatko, EV	1
Dinkova-Kostova, AT	2
Hiscott, J	1
Lin, R	1
Pauletti, A	2
Terrone, G	2
Shekh-Ahmad, T	2
Salamone, A	2
Rizzi, M	2
Pastore, A	2
Pascente, R	2
Liang, LP	2
Villa, BR	2
Abramov, AY	2
van Vliet, EA	2
Del Giudice, E	2
Aronica, E	2
Antoine, DJ	1
Patel, M	2
Walker, MC	2
Bai, Y	4
Chen, Q	3
Sun, YP	1
Lv, L	1
Zhang, LP	1
Liu, JS	1
Zhao, S	1
Wang, XL	1
Lee, IC	1
Kim, DY	1
Bae, JS	2
Meeran, SM	1
Tollefsbol, TO	1
Kang, K	1
Yu, M	1
Pereira, A	1
Fernandes, R	1
Crisóstomo, J	1
Seiça, RM	1
Sena, CM	1
Kerns, ML	2
Hakim, JMC	1
Zieman, A	1
Lu, RG	2
Coulombe, PA	2
Abdull Razis, AF	1
Konsue, N	1
Ioannides, C	1
Yang, G	2
Yeon, SH	1
Lee, HE	2
Kang, HC	1
Cho, YY	1
Lee, HS	1
Lee, JY	2
Xin, Y	2
Jiang, X	1
Zhou, S	1
Wang, Y	3
Wintergerst, KA	1
Cui, T	1
Ji, H	2
Tan, Y	4
Cai, L	4
Qu, J	1
Zheng, C	1
Zhang, P	1
Zhou, W	1
Cui, W	2
Mo, X	1
Gao, J	1
Silva Rodrigues, JF	1
Silva E Silva, C	1
França Muniz, T	1
de Aquino, AF	1
Neuza da Silva Nina, L	1
Fialho Sousa, NC	1
Nascimento da Silva, LC	1
de Souza, BGGF	1
da Penha, TA	1
Abreu-Silva, AL	1
de Sá, JC	1
Soares Fernandes, E	1
Grisotto, MAG	1
Lee, S	2
Choi, BR	2
LaFerla, FM	2
Park, JHY	1
Han, JS	2
Lee, KW	2
Jeffery, EH	1
Miller, MJ	1
Wallig, MA	1
Wu, Y	1
Sakurai, H	1
Morishima, Y	1
Ishii, Y	1
Yoshida, K	1
Nakajima, M	1
Tsunoda, Y	1
Hayashi, SY	1
Kiwamoto, T	1
Matsuno, Y	1
Kawaguchi, M	1
Hizawa, N	1
Taha, M	1
Cho, HY	2
Miller-DeGraff, L	2
Blankenship-Paris, T	1
Bell, DA	1
Lih, F	1
Deterding, L	1
Panduri, V	1
Morgan, DL	1
Reddy, AJ	1
Talalay, P	2
Kleeberger, SR	2
Nadeem, A	2
Ahmad, SF	2
Al-Harbi, NO	2
Attia, SM	1
Bakheet, SA	1
Ibrahim, KE	2
Alqahtani, F	2
Alqinyah, M	2
London, NR	1
Tharakan, A	1
Mendiola, M	1
Chen, M	1
Dobzanski, A	1
Sussan, TE	1
Zaykaner, M	1
Han, AH	1
Lane, AP	1
Sidhaye, V	1
Biswal, S	1
Ramanathan, M	1
Galea, I	1
Copple, IM	1
Howat, DW	1
Franklin, S	1
AlThagfan, SS	1
Al-Harbi, MM	1
Wu, W	1
Peng, G	1
Yang, F	1
Mu, Z	1
Han, X	1
Morroni, F	1
Tarozzi, A	1
Sita, G	1
Bolondi, C	1
Zolezzi Moraga, JM	1
Cantelli-Forti, G	1
Hrelia, P	1
Orozco-Sevilla, V	1
Naftalovich, R	1
Hoffmann, T	1
London, D	1
Czernizer, E	1
Dardik, A	1
Dardik, H	1
Liu, H	1
Smith, AJ	1
Lott, MC	1
Bao, Y	1
Bowater, RP	1
Reddan, JR	1
Wormstone, IM	1
Mokhtari, RB	1
Kumar, S	1
Islam, SS	1
Yazdanpanah, M	1
Adeli, K	1
Cutz, E	1
Yeger, H	1
Li, Q	1
Xia, J	1
Yao, Y	1
Gong, DW	1
Shi, H	2
Zhou, Q	2
Jiang, T	1
Tian, F	1
Zheng, H	1
Whitman, SA	1
Lin, Y	1
Zhang, N	1
Zhang, DD	1
Grandhi, BK	1
Thakkar, A	1
Wang, J	1
Prabhu, S	1
Hettinger, CL	1
Zhang, D	1
Rezvani, K	1
Nguyen, B	1
Luong, L	1
Naase, H	1
Vives, M	1
Jakaj, G	1
Finch, J	1
Boyle, J	1
Mulholland, JW	1
Kwak, JH	1
Pyo, S	1
de Luca, A	1
Athanasiou, T	1
Angelini, G	1
Anderson, J	1
Haskard, DO	2
Evans, PC	3
Ku, SK	1
Han, MS	1
Zhang, R	2
Miao, QW	1
Zhu, CX	1
Zhao, Y	1
Liu, L	1
An, L	1
Traka, MH	2
Melchini, A	2
Mithen, RF	2
Yager, JD	1
Pan, H	1
He, M	1
Liu, R	1
Brecha, NC	1
Yu, AC	1
Pu, M	1
Chi, X	1
Shen, N	1
Alina, A	1
Yang, S	1
Lin, S	1
Oguz, A	1
Kapan, M	1
Kaplan, I	1
Alabalik, U	1
Ulger, BV	1
Uslukaya, O	1
Turkoglu, A	1
Polat, Y	1
González-Polo, RA	1
Pizarro-Estrella, E	1
Yakhine-Diop, SM	1
Rodríguez-Arribas, M	1
Gómez-Sánchez, R	1
Pedro, JM	1
Fuentes, JM	1
Shirai, Y	1
Fujita, Y	1
Hashimoto, R	1
Ohi, K	1
Yamamori, H	1
Yasuda, Y	1
Ishima, T	1
Ushida, Y	3
Takeda, M	1
Hashimoto, K	2
Lavich, IC	1
de Freitas, BS	1
Kist, LW	1
Falavigna, L	1
Dargél, VA	1
Köbe, LM	1
Aguzzoli, C	1
Piffero, B	1
Florian, PZ	1
Bogo, MR	1
de Lima, MN	1
Schröder, N	1
Ambrecht, LA	1
Perlman, JI	1
McDonnell, JF	1
Zhai, Y	1
Qiao, L	1
Bu, P	1
Greaney, AJ	1
Maier, NK	1
Leppla, SH	1
Moayeri, M	1
Carrasco-Pozo, C	1
Tan, KN	1
Borges, K	1
Kikuchi, M	1
Shiozawa, H	1
Umeda, R	1
Tsuruya, K	1
Aoki, Y	1
Nishizaki, Y	1
Yin, XP	1
Chen, ZY	1
Zhou, J	2
Wu, D	1
Bao, B	1
Townsend, BE	1
Johnson, RW	1
Wu, S	1
Gao, Q	1
Zhao, P	1
Gao, Y	1
Xi, Y	1
Liang, Y	1
Ma, Y	1
Liu, CM	1
Peng, CY	1
Liao, YW	1
Lu, MY	1
Tsai, ML	1
Yeh, JC	1
Yu, CH	1
Yu, CC	1
Houghton, CA	1
Fassett, RG	1
Coombes, JS	1
Hernández-Rabaza, V	2
Cabrera-Pastor, A	2
Taoro-González, L	2
Malaguarnera, M	1
Agustí, A	2
Llansola, M	2
Felipo, V	2
Sasaki, M	1
Shinozaki, S	1
Shimokado, K	1
Khan, S	1
Karmokar, A	1
Howells, L	1
Thomas, AL	1
Bayliss, R	1
Gescher, A	1
Brown, K	1
Gonzalez-Usano, A	1
Balzano, T	1
Zhao, X	2
Lorent, K	1
Wilkins, BJ	1
Marchione, DM	1
Gillespie, K	1
Waisbourd-Zinman, O	1
So, J	1
Koo, KA	1
Shin, D	1
Porter, JR	1
Wells, RG	1
Blair, I	1
Pack, M	1
Hakim, JM	1
Guo, Y	2
Berroth, A	1
Kaspar, RL	1
Matsui, T	1
Nakamura, N	1
Ojima, A	1
Nishino, Y	1
Yamagishi, SI	1
Moreno, FS	1
Heidor, R	1
Pogribny, IP	1
Ebihara, S	1
Tajima, H	1
Ono, M	1
Holloway, PM	1
Gillespie, S	1
Vital, SA	1
Nguyen, V	1
Alexander, JS	1
Gavins, FNE	1
Xu, H	1
Fu, S	1
Chen, Y	1
Cai, Z	1
Wang, Z	1
Xu, Z	1
Wang, S	3
Chen, J	3
Wintergerst, K	1
Zheng, Y	1
Sun, J	1
Chen, B	1
Wu, L	1
Yang, Y	1
Cheng, X	1
Hu, Z	1
Cai, X	1
Sun, X	2
Yan, H	1
Ye, J	1
Shen, J	1
Cao, P	1
Wen, L	1
Dong, M	1
Yang, SH	1
Long, M	1
Yu, LH	1
Li, P	1
Gao, F	1
Liu, MD	1
He, JB	1
Yang, H	1
Hwang, Y	1
Tai, HC	1
Chung, SD	1
Chien, CT	1
Yu, HJ	1
Zhang, JC	1
Yao, W	1
Dong, C	1
Ren, Q	1
Ma, M	1
Han, M	1
Nazmy, EA	1
El-Khouly, OA	1
Atef, H	1
Said, E	1
Wu, H	1
Liu, F	1
Deng, Z	1
Rong, Y	1
Teng, Y	1
Mu, J	1
Zhuang, X	1
Tseng, M	1
Samykutty, A	1
Zhang, L	1
Yan, J	1
Miller, D	1
Suttles, J	1
Zhang, HG	1
Cho, NP	1
Han, HS	1
Leem, DH	1
Choi, IS	1
Jung, JY	1
Moon, KS	1
Choi, KH	1
Soh, Y	1
Kong, G	1
Cho, SD	1
Choi, SH	1
Imani, F	1
Walters, D	1
Melendi, GA	1
Polack, FP	1
Shankar, S	1
Ganapathy, S	1
Srivastava, RK	1
Dash, PK	3
Orsi, SA	1
Zhang, M	1
Moore, AN	2
Dickinson, SE	1
Melton, TF	1
Olson, ER	1
Zhang, J	1
Saboda, K	1
Bowden, GT	1
Zakkar, M	1
Van der Heiden, K	1
Luong, le A	1
Chaudhury, H	1
Cuhlmann, S	1
Hamdulay, SS	1
Krams, R	1
Edirisinghe, I	1
Rahman, I	1
Carlsen, H	1
Mason, JC	1
Piao, CS	1
Gao, S	1
Lee, GH	1
Kim, DS	1
Park, BH	1
Chae, SW	1
Chae, HJ	1
Ping, Z	1
Liu, W	1
Kang, Z	1
Cai, J	1
Wang, Q	1
Cheng, N	1
Zhang, JH	1
Spinks, CA	1
Doleman, JF	1
Ball, RY	1
Mills, RD	1
Hong, Y	1
Yan, W	1
Chen, S	1
Sun, CR	1
Zhang, JM	1
Jakubikova, J	1
Cervi, D	1
Ooi, M	1
Kim, K	1
Nahar, S	1
Klippel, S	1
Cholujova, D	1
Leiba, M	1
Daley, JF	1
Delmore, J	1
Negri, J	1
Blotta, S	1
McMillin, DW	1
Hideshima, T	1
Richardson, PG	1
Sedlak, J	1
Anderson, KC	1
Mitsiades, CS	1
Choi, K	1
Mitra, S	1
Sarna, SK	1
de Rivero Vaccari, JP	1
Diaz, P	1
German, R	1
Marcillo, AE	1
Keane, RW	1
Negi, G	1
Kumar, A	1
Sharma, SS	1
Okada, K	1
Warabi, E	1
Sugimoto, H	1
Horie, M	1
Tokushige, K	1
Ueda, T	1
Harada, N	1
Taguchi, K	1
Hashimoto, E	1
Itoh, K	1
Ishii, T	1
Utsunomiya, H	1
Shoda, J	1
Lee, CM	1
Kim, YD	1
Chung, SW	1
Jung, ID	1
Noh, KT	1
Park, JW	1
Heo, DR	1
Shin, YK	1
Seo, JK	1
Park, YM	1
Benedict, AL	1
Mountney, A	1
Hurtado, A	1
Bryan, KE	1
Schnaar, RL	1
Porritt, MJ	1
Andersson, HC	1
Hou, L	1
Nilsson, Å	1
Pekna, M	1
Pekny, M	1
Nilsson, M	1
Yanaka, A	1
Sato, J	1
Ohmori, S	1
Garber, K	1
Miao, X	1
Luo, P	1
Rane, MJ	1
Miao, L	1
Kim, HV	1
Kim, HY	1
Ehrlich, HY	1
Choi, SY	1
Kim, Y	1
Clifton, GL	1
Kobori, N	1
Aronowski, J	1
Tanito, M	1
Li, F	1
Zhou, X	1
Zaharia, A	1
Yodoi, J	1
McGinnis, JF	1
Cao, W	1
Trinh, K	1
Moore, K	1
Wes, PD	1
Muchowski, PJ	1
Dey, J	1
Andrews, L	1
Pallanck, LJ	1